New Hampshire Gov. Kelly Ayotte vetoed legislation Wednesday that would have allowed the state's medical marijuana dispensaries to cultivate cannabis in greenhouses, dealing a blow to efforts to reduce patient costs.
Senate Bill 468, sponsored by Republican Sen. Howard Pearl of Loudon, passed with bipartisan support but met resistance from the governor's office. "I do not support expanding the cultivation of marijuana in our state," Ayotte said in her veto message.
The bill would have permitted New Hampshire's four licensed alternative treatment centers to grow cannabis in greenhouse facilities, a move supporters argued would lower production costs and increase supply for the state's roughly 8,000 registered medical marijuana patients. Currently, the centers must cultivate indoors under strict environmental controls.
The Economics of Indoor vs. Greenhouse
Greenhouse cultivation typically costs 30-50% less than indoor growing operations, according to cannabis industry analysts. The method uses natural sunlight supplemented by artificial lighting, reducing electricity costs while maintaining environmental control.
Pearl and other supporters framed the legislation as a cost-saving measure for patients. New Hampshire's medical cannabis program, established in 2013, remains among the more restrictive in the Northeast. The state has no adult-use market, and medical prices often exceed those in neighboring Massachusetts and Maine, where recreational sales are legal.
But Ayotte, who took office in January, has signaled a more cautious approach to cannabis policy than her predecessor. The Republican governor has not indicated support for recreational legalization and appears skeptical of medical program expansion.
What This Means for Patients
The veto leaves New Hampshire's medical cannabis supply chain unchanged. Patients will continue paying premium prices for products grown in expensive indoor facilities. Industry observers note that without greenhouse cultivation, the state's alternative treatment centers face higher overhead that gets passed to consumers.
New Hampshire's medical program allows cannabis for 10 qualifying conditions, including cancer, PTSD, and chronic pain. Yet the state's patient count remains relatively low compared to other medical-only programs, which advocates partly attribute to high costs and limited access.
The legislature could attempt a veto override, though that would require a two-thirds vote in both chambers. The bill's bipartisan support suggests override efforts might gain traction, but Republican leadership has not indicated whether they'll pursue that path.
Regional Context
New Hampshire stands out in New England as the only state without either recreational cannabis sales or plans to implement them. Vermont, Maine, Massachusetts, Connecticut, and Rhode Island all have adult-use programs. Even conservative-leaning New Hampshire has seen multiple legalization bills introduced in recent sessions, though none have advanced.
The greenhouse veto comes as other states expand cultivation options to drive down costs. Michigan recently allowed outdoor growing for licensed businesses. Missouri is considering similar greenhouse provisions. Industry groups argue that cultivation flexibility helps medical programs remain competitive and accessible.
For now, New Hampshire's medical cannabis patients will continue relying on indoor-grown products at current price points. Whether the legislature pushes back against Ayotte's veto remains the next question in the state's cannabis policy debate.
This article is based on original reporting by www.marijuanamoment.net.
